« Previous article
Solus One Salmonella...

10th February 2020  Product update: rapidmicrobiology staff writer

New POC Breath Test for Virulent Lung Infections Receives Funding


The AV BreathTest™ is a drug/device combination for detecting and monitoring virulent lung infections - determining whether the cause is urease positive bacterial pathogens or a viral infection, the test can then guide appropriate use and selection of antibiotics.

It's based on the presence of the urease enzyme found in certain bacterial species that cause pneumonia, such as S. aureus, P. aeruginosa, Klebsiella and H. influenzae. Live urease-containing bacteria can be detected using inhaled 13C-urea which is converted by these bacteria to labelled carbon dioxide (13C02) and ammonia. The non-radioactive, isotopic ratio of 13C02 to naturally occurring 12C02 is measured in the exhaled breath of the patient and is akin to an infection thermometer for the lungs.

AVISA will use the funds for product manufacturing and pivotal clinical trials that are required to seek U.S. FDA approval for the Company's AV BreathTest™.

    

Tags:

Date Published: 10th February 2020

Source article link: https://www.prnewswire.com/news-releases/avisa-pharma-inc-announces-financing-agreement-with-global-emerging-markets-limited-300997884.html

Note: This content has been edited by a rapidmicrobiology staff writer for style and content.


View full company details